Shows
BioBusiness.TV, the podcast! ver2TARG CEO Interview - Part 1You are Watching:
Targanta's Antibiotic Shows Promise, And Overcomes the Challenges it Faced When Previously Developped at Lilly and InterMune
Oritavancin is Targanta's lead compound. Initially developped at Lilly, it was then sold to InterMune, and picked up by Targanta in an equity deal. Mark Leuchtenberger explains the history of the drug, and in doing so faces further probe from Joel Sendek as to the corporate and medical challenges the drug had to face in its earlier days. Mark explains how they were overcome in Targanta's hands, and the true potential of the was drug unlocked.
This interview was conducted...
2008-09-1806 minBioBusiness.TV, the podcast! ver2TARG CEO Interview - Part 2You are Watching:
Targanta Confident and Prepared for FDA Panel Review of Lead Compound Oritavancin
Mark and Joel delve into the clincal trials and regulatory process, around Targanta's Lead compound Oritavancin. Mark describes the current response of the FDA, and completed clinial site audits. He then continues to explain his team is expecting a panel meeting and is fully prepared to assit the panel's review of the drug. This panel could be expected as early as November of this year. When Joel inquires about the release of simplified data, which might differentiate Oritavancin for its competitors, Mark tells him about...
2008-09-1801 minBioBusiness.TV, the podcast! ver2TARG CEO Interview - Part 3You are Watching:
Targanta Attacking $1.2Bn Antibiotic Market with Resistance Adverse Drug, Do-or-Die!
Mark and Joel review the competitive landscape for Targanta's Antibiotic and Lead Compound, Oritavancin. Key differentiators include shorter course of treatment, lack of monitoring and dosing adjustment, efficacy and coverage. With a growing $1.2bn market, Mark still sees an unmet medical need in resistance adverse antibiotics, which Targanta is looking to address with focus, passion, and a Do-or-Die attitude. A Phase 3 trial, validating a single dose treatment against a standard of care competitor is expected to run next year.
This interview was conducted at the NASDAQ Marketsite...
2008-09-1801 min